Drugs / Sunphenon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04300855 | Aug 2020 → Feb 2027 expected | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01928485 | Aug 2013 → Oct 2016 | prostate carcinoma | Sanjay Gupta PhD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sunphenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04300855 ↗ |
| Known as | Green Tea Catechin | “This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation...” NCT04300855 ↗ |
| Route | Oral | “Patients receive green tea extract orally (PO) once daily (QD) for 52 weeks in the absence of disease progression or unacceptable toxicity.” NCT01928485 ↗ |